Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2003 1
2005 4
2006 3
2007 3
2008 3
2009 4
2010 2
2011 3
2013 2
2015 1
2016 3
2017 2
2020 1
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
[Pustular psoriasis].
Weisenseel P, Wilsmann-Theis D, Kahl C, Reich K, Mössner R. Weisenseel P, et al. Hautarzt. 2016 Jun;67(6):445-53. doi: 10.1007/s00105-016-3804-4. Hautarzt. 2016. PMID: 27240667 Review. German.
[Inverse psoriasis].
Weisenseel P, Reich K. Weisenseel P, et al. Hautarzt. 2015 Jun;66(6):408-12. doi: 10.1007/s00105-015-3628-7. Hautarzt. 2015. PMID: 25896586 Review. German.
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias EJ, Bartz H, Taut FJH, Reich K. Eyerich K, et al. Among authors: weisenseel p. BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822. BMJ Open. 2021. PMID: 34518264 Free PMC article.
[Comorbidities in psoriasis].
Weisenseel P, Prinz JC. Weisenseel P, et al. Dtsch Med Wochenschr. 2010 Jul;135(28-29):1446-50. doi: 10.1055/s-0030-1262432. Epub 2010 Jul 7. Dtsch Med Wochenschr. 2010. PMID: 20614408 Review. German. No abstract available.
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Menter A, Arenberger P, Balser S, Beissert S, Cauthen A, Czeloth N, Soung J, Jazayeri S, Weisenseel P, Jayadeva G. Menter A, et al. Among authors: weisenseel p. Expert Opin Biol Ther. 2021 Jan;21(1):87-96. doi: 10.1080/14712598.2021.1851362. Epub 2020 Dec 29. Expert Opin Biol Ther. 2021. PMID: 33317345 Clinical Trial.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: weisenseel p. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis.
Reich K, Deinzer J, Fiege AK, von Gruben V, Sack AL, Thraen A, Weisenseel P, Breuer K, Jäckle S, Meier M. Reich K, et al. Among authors: weisenseel p. J Allergy Clin Immunol. 2016 Jun;137(6):1882-1884.e6. doi: 10.1016/j.jaci.2016.01.016. Epub 2016 Mar 15. J Allergy Clin Immunol. 2016. PMID: 26993034 Free article. Clinical Trial. No abstract available.
Topical treatment of perianal eczema with tacrolimus 0.1%.
Schauber J, Weisenseel P, Ruzicka T. Schauber J, et al. Among authors: weisenseel p. Br J Dermatol. 2009 Dec;161(6):1384-6. doi: 10.1111/j.1365-2133.2009.09345.x. Epub 2009 Jul 3. Br J Dermatol. 2009. PMID: 19575757
36 results